Phase I Trial: SABR and Ipilimumab-Letter.

Hiniker, Susan M; Reddy, Sunil A; Swetter, Susan M; Knox, Susan J

Hiniker, Susan M; Reddy, Sunil A; Swetter, Susan M; Knox, Susan J.

Afiliación

Hiniker SM; Department of Radiation Oncology, Stanford University Medical Center and Cancer Institute, Stanford, California. shiniker@stanford.edu.
Reddy SA; Department of Medicine, Division of Oncology, Stanford University Medical Center and Cancer Institute, Stanford, California.
Swetter SM; Department of Dermatology, Pigmented Lesion and Melanoma Program, Stanford University Medical Center and Cancer Institute, Stanford, California.
Knox SJ; Dermatology Service, Veterans Affairs Palo Alto Health Care System, Palo Alto, California.

Clin Cancer Res ; 23(1): 320, 2017 01 01.

Article en En | MEDLINE | ID: mdl-28049160

Asunto(s)

Ipilimumab; Linfocitos T; Humanos; Neoplasias Pulmonares/cirugía; Radiocirugia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfocitos T / Ipilimumab Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google